|Title||Enhancing Communication for People in Late-Stage ALS Using an fNIRS-Based BCI System.|
|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Borgheai, SBahram, McLinden, J, Zisk, AHillary, Hosni, SIsmail, Deligani, RJafari, Abtahi, M, Mankodiya, K, Shahriari, Y|
|Journal||IEEE Trans Neural Syst Rehabil Eng|
|Keywords||Amyotrophic Lateral Sclerosis, brain-computer interfaces, Communication, Electroencephalography, Humans, Spectroscopy, Near-Infrared|
OBJECTIVE: Brain-computer interface (BCI) based communication remains a challenge for people with later-stage amyotrophic lateral sclerosis (ALS) who lose all voluntary muscle control. Although recent studies have demonstrated the feasibility of functional near-infrared spectroscopy (fNIRS) to successfully control BCIs primarily for healthy cohorts, these systems are yet inefficient for people with severe motor disabilities like ALS. In this study, we developed a new fNIRS-based BCI system in concert with a single-trial Visuo-Mental (VM) paradigm to investigate the feasibility of enhanced communication for ALS patients, particularly those in the later stages of the disease.
METHODS: In the first part of the study, we recorded data from six ALS patients using our proposed protocol (fNIRS-VM) and compared the results with the conventional electroencephalography (EEG)-based multi-trial P3Speller (P3S). In the second part, we recorded longitudinal data from one patient in the late locked-in state (LIS) who had fully lost eye-gaze control. Using statistical parametric mapping (SPM) and correlation analysis, the optimal channels and hemodynamic features were selected and used in linear discriminant analysis (LDA).
RESULTS: Over all the subjects, we obtained an average accuracy of 81.3%±5.7% within comparatively short times (
SIGNIFICANCE: Our findings indicate the potential efficacy of our proposed system for communication and control for late-stage ALS patients.
|Alternate Journal||IEEE Trans Neural Syst Rehabil Eng|
|PubMed Central ID||PMC7288752|
|Grant List||P20 GM103430 / GM / NIGMS NIH HHS / United States |
P41 EB018783 / EB / NIBIB NIH HHS / United States